Another important class of kinase inhibitor drugs are those targeting ABL1, of which a re-arranged form, i.e., BCR-ABL1, drives Philadelphia chromosome-positive chronic myelogenous leukemia (CML). This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.